首页> 外文期刊>Experimental and clinical transplantation >Malignancies After Heart Transplant
【24h】

Malignancies After Heart Transplant

机译:心脏移植后的恶性肿瘤

获取原文
       

摘要

Along with graft vasculopathy, malignancies com-prise a major complication after heart transplant, with a rate of occurrence of 39.1% in 10 years. Skin cancers and posttransplant lymphoproliferative disorder are more common in adults, whereas lymphoma is more often shown in children. A major cause of malignancies after heart transplant is the use of increased doses of prophylactics needed during immunosuppressive therapy. Data, however, are scarce regarding the association between a particular immunosuppressive drug and a post-transplant malignancy. Compared with the general population, recipients have a higher incidence of malignancies after heart transplant, with an early onset and more aggressive disease. Solid tumors known to occur in heart transplant recipients include lung cancer, bladder and prostate carcinoma, adenocarcinoma of the oral cavity, stomach cancer, and bowel cancer, although the incidence is rare. The risk factors for development of a malignancy after heart transplant are the same as for the nontransplant population.
机译:与移植血管病变一起,恶性肿瘤是心脏移植后的主要并发症,在10年内发生率为39.1%。皮肤癌和移植后的淋巴增生性疾病在成年人中更为常见,而淋巴瘤在儿童中更常见。心脏移植后发生恶性肿瘤的主要原因是在免疫抑制治疗期间需要增加剂量的预防药物。但是,关于特定免疫抑制药物与移植后恶性肿瘤之间关联的数据很少。与普通人群相比,接受者在心脏移植后发生恶性肿瘤的几率更高,且发病较早且更具侵略性。已知发生在心脏移植受者中的实体瘤包括肺癌,膀胱癌和前列腺癌,口腔腺癌,胃癌和肠癌,尽管这种情况很少见。心脏移植后发生恶性肿瘤的危险因素与非移植人群相同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号